Solaxa
Early Stage
Restoring people's lives suffering from nerve dysfunction with FDA approved drug
Overview
Raised: $0
Total Commitments ($USD)
Platform
Wefunder
Start Date
05/24/2023
Close Date
04/29/2024
Min. Goal
$50,000
Max. Goal
$1,200,000
Min. Investment
$100
Security Type
SAFE
Series
Seed
SEC Filing Type
RegCF
Early Bird Val. Cap
$12,500,000
Valuation Cap
$15,000,000
Discount
10%
Rolling Commitments ($USD)
Status
Active
Reporting Date
06/04/2023
Days Remaining
330
% of Min. Goal
0%
% of Max. Goal
0%
Likelihood of Max
Avg. Daily Raise
$0
Momentum
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2021
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B2C
Margin
Medium
Capital Intensity
High
Solaxa, with a valuation of $15 million, is raising funds on Wefunder. The company is revolutionizing the treatment of nerve dysfunction with its FDA-approved drug. The company is clinical-stage ready and neuro-focused and is developing better treatments for hereditary ataxias and nerve injury. The drug targeting nerve dysfunction caused by hereditary ataxia is called Ampyra or dalfampridine and is already FDA-approved to improve walking in adults with multiple sclerosis. Christian Walker founded Solaxa in February 2021. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1.2 million. The campaign proceeds will be used for salaries, consulting and legal services to obtain orphan drug designation, pre-clinical research and development, product development and manufacturing, and company operations.
Summary Profit and Loss Statement
| FY 2022 | FY 2021 | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$1,550 |
$0 |
| ||
| ||
|
Net Income |
$-200,342 |
$-17,652 |
Summary Balance Sheet
| FY 2022 | FY 2021 | |
|---|---|---|
|
Cash |
$287 |
$55,026 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$319,840 |
$72,358 |
|
Short-Term Debt |
$302,262 |
$0 |
|
Long-Term Debt |
$84,062 |
$0 |
|
Total Liabilities |
$386,324 |
$0 |
Financials as of: 05/24/2023
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Ratings 
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.